High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.
Eagerly pursuing all the latest fads and trends.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?